Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells 6,007 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,007 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72. Following the completion of the sale, the chief executive officer now owns 301,408 shares of the company’s stock, valued at approximately $9,030,183.68. This represents a 1.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS traded up $0.19 during trading on Tuesday, reaching $30.13. The company had a trading volume of 1,461,289 shares, compared to its average volume of 2,274,031. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a fifty day moving average of $31.89 and a two-hundred day moving average of $33.31. The stock has a market capitalization of $3.75 billion, a P/E ratio of -14.84 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.17) earnings per share. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in APLS. Envestnet Asset Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after acquiring an additional 39,931 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. Profund Advisors LLC raised its holdings in Apellis Pharmaceuticals by 90.7% during the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after acquiring an additional 20,435 shares during the period. Algert Global LLC lifted its position in shares of Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after acquiring an additional 71,650 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth about $1,370,000. Institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

APLS has been the subject of a number of recent analyst reports. Robert W. Baird reduced their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. William Blair started coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating on the stock. Citigroup cut their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Needham & Company LLC lowered their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).